Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer

You may be eligible if

• Histologically confirmed ovarian epithelial or primary peritoneal carcinoma
• * Persistent or recurrent disease
• Measurable or evaluable disease
• * Measurable disease is defined as at least 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques (including palpation, plain x-ray, CT scan, or MRI) OR ≥ 10 mm by spiral CT scan
• * Evaluable disease is defined as at least 1 of the following:
• * CA 125 ≥ 2 times upper limit of normal (ULN)
• * Ascites and/or pleural effusion attributed to tumor
• * Solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST definition for target lesions
• Must have received 1 prior platinum-based chemotherapeutic regimen for primary disease, including carboplatin, cisplatin, or another organoplatinum compound
• * Initial treatment may have included high-dose therapy, consolidation, or extended therapy administered after surgical or non-surgical assessment
• * Platinum-resistant according to 1 of the following criteria:
• * Treatment-free interval of \< 12 months after platinum therapy
• * Disease progression during platinum-based therapy
• * Persistent disease after a platinum-based regimen
• Ineligible for higher priority GOG protocol (e.g., any active phase III GOG protocol for the same patient population)
• No brain metastases
• Performance status - GOG 0-2 (for patients who received 1 prior treatment regimen)
• Performance status - GOG 0-1 (for patients who received 2 prior treatment regimens)
• Absolute neutrophil count ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• No known bleeding diathesis
• Bilirubin ≤ 1.5 times ULN
• SGOT ≤ 2.5 times ULN
• Alkaline phosphatase ≤ 2.5 times ULN
• Creatinine ≤ 1.5 times ULN
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia
• No uncontrolled hypertension
• Able to take oral medication
• No bowel obstruction or persistent vomiting
• No requirement for parenteral feedings
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective barrier contraception during and for 3 months after study participation
• No sensory or motor neuropathy \> grade 1
• No active or ongoing infection requiring antibiotics
• No history of allergic reaction attributed to compounds of similar chemical or biological composition to sorafenib
• No serious chronic skin conditions (i.e., psoriasis or dermatitis) that would preclude study participation
• No psychiatric illness or social situation that would preclude study compliance
• No other uncontrolled illness
• No other invasive malignancy within the past 5 years except nonmelanoma skin cancer
• At least 3 weeks since prior immunologic agents for the malignancy
• More than 4 weeks since prior mouse antibodies (for patients with evaluable disease only)
• No concurrent prophylactic growth factors (e.g., filgrastim \[G-CSF\])
• No concurrent prophylactic thrombopoietic agents except in the case of recurrent grade 4 thrombocytopenia
• No other concurrent biological agents for the primary tumor
• See Disease Characteristics
• More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
• No prior non-cytotoxic chemotherapy for persistent or recurrent disease
• No concurrent chemotherapy for the primary tumor
• At least 1 week since prior hormonal therapy for the malignancy
• No concurrent hormonal therapy for the primary tumor
• * Concurrent hormone replacement therapy allowed
• More than 4 weeks since prior radiotherapy and recovered
• No prior radiotherapy to \> 25% of marrow-bearing areas
• No concurrent radiotherapy
• More than 4 weeks since prior surgery involving the peritoneum or pleura (for patients with evaluable disease only)
• Recovered from prior surgery
• At least 3 weeks since other prior therapy for the malignancy
• No more than 1 additional prior cytotoxic regimen for persistent or recurrent disease
• No prior sorafenib
• No prior anticancer treatment that would preclude study participation
• No concurrent therapeutic oral anticoagulation therapy (i.e., warfarin)
• * Concurrent prophylactic anticoagulation (i.e., low-dose warfarin) for central venous access devices allowed provided INR is \< 1.5
• No concurrent combination antiretroviral therapy for HIV-positive patients
• No other concurrent investigational or commercial agents or therapies for the malignancy